Table 4.

Incidence of venous thromboembolism among medical inpatients receiving enoxaparin versus UFH prophylaxis by dosage and duration of prophylaxis received

			Outcome (N [%])
Prophylaxis Received/Dosage or Days	N	% of Patients	DVT	PE	VTE (DVT and/or PE)
Dosage:
Enoxaparin
30–40 mg	186	38.8%	0 (0.0)	0 (0.0)	0 (0.0)
50–60 mg	293	61.2%	8 (2.7)	0 (0.0)	8 (2.7)
UFH
5,000-<10,000 IU	414	14.5%	47 (11.4)	8 (1.93)	52 (12.6)
10,000 IU	2,221	78.0%	109 (4.9)	23 (1.04)	121 (5.4)
>10,000–15,000 IU	214	7.5%	7 (3.3)	1 (0.5)	7 (3.3)
Prophylaxis days:
Enoxaparin
1–2 days	74	15.4%	4 (5.4)	0 (0.0)	4 (5.4)
3–4 days	36	7.5%	2 (5.6)	0 (0.0)	2 (5.6)
5–6 days	123	25.7%	2 (1.6)	0 (0.0)	2 (1.6)
> 6 days	246	51.4%	0 (0.0)	0 (0.0)	0 (0.0)
UFH
1–2 days	831	29.3%	109 (13.1)	22 (2.7)	120 (14.4)
3–4 days	227	8.0%	21 (9.25)	2 (0.9)	23 (10.1)
5–6 days	608	21.4%	15 (2.5)	4 (0.7)	15 (2.5)
> 6 days	1,171	41.3%	18 (1.5)	4 (0.3)	22 (1.9)

Bold indicates p for trend <0.05